Search details
1.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 783-794, 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-38381664
2.
Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Am J Physiol Gastrointest Liver Physiol
; 326(2): G120-G132, 2024 02 01.
Article
in English
| MEDLINE | ID: mdl-38014444
3.
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
Hepatology
; 2023 Dec 20.
Article
in English
| MEDLINE | ID: mdl-38117036
4.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology
; 78(2): 397-415, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37386786
5.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
J Hepatol
; 77(2): 353-364, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35367282
6.
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Liver Int
; 42(1): 112-123, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34403559
7.
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Aliment Pharmacol Ther
; 59(2): 201-216, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37877759
8.
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Aliment Pharmacol Ther
; 59(2): 186-200, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37904314
9.
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
J Rheumatol
; 44(3): 374-379, 2017 03.
Article
in English
| MEDLINE | ID: mdl-27980008
10.
The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.
Hepatol Commun
; 1(7): 663-674, 2017 09.
Article
in English
| MEDLINE | ID: mdl-29404484
11.
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Lancet Gastroenterol Hepatol
; 2(10): 716-726, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28818518
12.
A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.
Arthritis Rheumatol
; 68(8): 2027-34, 2016 08.
Article
in English
| MEDLINE | ID: mdl-26989892
13.
N-myristoylation of Arf proteins in Candida albicans: an in vivo assay for evaluating antifungal inhibitors of myristoyl-CoA: protein N-myristoyltransferase.
Microbiology (Reading)
; 143 ( Pt 2): 357-366, 1997 Feb.
Article
in English
| MEDLINE | ID: mdl-9043113
Results
1 -
13
de 13
1
Next >
>>